{"id":628,"date":"2016-03-18T08:47:53","date_gmt":"2016-03-18T12:47:53","guid":{"rendered":"https:\/\/patents.harnessip.com\/?p=628"},"modified":"2016-03-23T08:56:17","modified_gmt":"2016-03-23T12:56:17","slug":"anda-filings-create-personal-jurisdiction-everywhere","status":"publish","type":"post","link":"https:\/\/patents.harnessip.com\/?p=628","title":{"rendered":"ANDA Filings Create Personal Jurisdiction Everywhere"},"content":{"rendered":"<p>In\u00a0<em>Acorda Therapeutics, Inc. v, Mylan Pharmaceutical Inc.<\/em>, [2015-1460) (March 18, 2016), the Federal Circuit affirmed that Mylan was subject to specific personal jurisdiction in the District of Delaware, \u00a0The Federal Circuit said that under Fed. R. Civ. P. 4(k)(1)(A), the district court had personal jurisdiction over Mylan if Mylan would be \u201csubject to the jurisdiction of a court of general jurisdiction in the state where the district court is located,\u201d and there is no dispute that Mylan would be subject to Delaware courts\u2019 jurisdiction under Delaware\u2019s long-arm statute, Del. Code Ann. tit. 10, \u00a7 3104, as long as Delaware\u2019s exercise of personal jurisdiction over Mylan would be consistent with the Fourteenth Amendment\u2019s Due Process Clause.<\/p>\n<p>The Federal Circuit noted that\u00a0Mylan had taken the costly, significant step of applying to the FDA for approval to engage in future activities\u2014including the marketing of its generic drugs\u2014 that will be purposefully directed at Delaware (and, it is undisputed, elsewhere). The Federal Circuit said that if Mylan had already begun its deliberate marketing of these drugs in Delaware, there is no doubt that it could be sued for infringement in Delaware. The Federal Circuit concluded that\u00a0the minimum-contacts standard is satisfied by the particular actions Mylan has already taken\u2014its ANDA filings\u2014for the purpose of\u00a0engaging in injury-causing and allegedly wrongful marketing conduct in Delaware.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In\u00a0Acorda Therapeutics, Inc. v, Mylan Pharmaceutical Inc., [2015-1460) (March 18, 2016), the Federal Circuit affirmed that Mylan was subject to specific personal jurisdiction in the District of Delaware, \u00a0The Federal Circuit said that under Fed. R. Civ. P. 4(k)(1)(A), the &hellip; <a href=\"https:\/\/patents.harnessip.com\/?p=628\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-628","post","type-post","status-publish","format-standard","hentry","category-jurisdiction"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts\/628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=628"}],"version-history":[{"count":1,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts\/628\/revisions"}],"predecessor-version":[{"id":629,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts\/628\/revisions\/629"}],"wp:attachment":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}